Sagimet Biosciences Inc. Series A (SGMT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sagimet Biosciences Inc. Series A $1.81, price $9.14, upside -80.2%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sagimet Biosciences Inc. Series A Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
39‑month range $1.90 – $18.42 · fair‑value band $1.19 – $2.26 · the $9.14 price screens above the $1.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Follow Sagimet Biosciences Inc. Series A Common Stock in your weekly email
Every Wednesday you see whether Sagimet Biosciences Inc. Series A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Show more
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Stock analysis
Sagimet Biosciences Inc. Series A Common Stock (SGMT) currently trades at $9.14, while our model-based Fair Value estimate is $1.81, 80.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.19 (bear) to $2.26 (bull), the price of $9.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Sagimet Biosciences Inc. Series A Common Stock reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$51.0M in FY2025.
Key figures
Market cap $689M · EPS (TTM) $−1.26 · Return on equity −24.4% · Return on assets (EBIT) −49.8% · Free cash flow −$45.7M · Net cash $34.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 101% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, SGMT screens richer than that median.
Fair Value models
Bear $1.19Fair Value $1.81Bull $2.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (55 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Sagimet Biosciences Inc. Series A Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−80.7% · Bottom 25%
Profitability
Return on assets−16.4% · Below median
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sagimet Biosciences Inc. Series A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/SGMT
Frequently asked questions
Is Sagimet Biosciences Inc. Series A (SGMT) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $1.81 versus a price of $9.14, about −80% upside (overvalued).
What is the fair value of SGMT?
Our model-based fair value for Sagimet Biosciences Inc. Series A Common Stock is $1.81 (as of Sep 29, 2026), built from audited fundamentals. The current price: $9.14.
What is the quality score of SGMT?
Sagimet Biosciences Inc. Series A Common Stock has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sagimet Biosciences Inc. Series A (SGMT)?
Our model-based price target is the fair value of $1.81 (as of Sep 29, 2026) from 1 valuation models. Cautious scenario $1.19, optimistic scenario $2.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Sagimet Biosciences Inc. Series A Common Stock stock forecast for 2026?
Our models put fair value at $1.81, about −80% upside versus a price of $9.14 (overvalued). Cautious scenario $1.19, optimistic scenario $2.26. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sagimet Biosciences Inc. Series A (SGMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sagimet Biosciences Inc. Series A Common Stock it is $1.81 per share (as of Sep 29, 2026), against a price of $9.14. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sagimet Biosciences Inc. Series A Common Stock stock overvalued or undervalued in 2026?
As of Sep 29, 2026, SGMT trades above its calculated fair value: price $9.14, fair value $1.81, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SGMT?
No. The price is what the market pays today ($9.14); the fair value is what the company's own numbers justify ($1.81). For Sagimet Biosciences Inc. Series A Common Stock the two are $7.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sagimet Biosciences Inc. Series A Common Stock worth?
The market values Sagimet Biosciences Inc. Series A Common Stock at about $689M (market capitalisation, as of Sep 29, 2026). Per share that is $9.14; our models calculate a fair value of $1.81 per share.
What do the bullish and bearish scenarios say about SGMT?
Our models span a range for Sagimet Biosciences Inc. Series A Common Stock: cautious scenario $1.19, base $1.81, optimistic $2.26 per share (as of Sep 29, 2026, price $9.14). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sagimet Biosciences Inc. Series A (SGMT)?
Balance-sheet figures for Sagimet Biosciences Inc. Series A Common Stock (as of Sep 29, 2026): return on equity −24.4%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is SGMT from its 52-week high?
Sagimet Biosciences Inc. Series A Common Stock trades at $9.14, about 18% below its 52-week high of $11.17 and 101% above the low of $4.55 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.81 is for.
Which stocks are comparable to Sagimet Biosciences Inc. Series A Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sagimet Biosciences Inc. Series A Common Stock stock attractive at the current price?
The data as of Sep 29, 2026: price $9.14, calculated fair value $1.81 (−80%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SGMT calculated?
We run Sagimet Biosciences Inc. Series A Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.81, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sagimet Biosciences Inc. Series A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sagimet Biosciences Inc. Series A (SGMT)?
The closing price on Oct 2, 2026 was $9.14. Our model-based fair value is $1.81, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sagimet Biosciences Inc. Series A Common Stock right now?
The price sits above even our optimistic bull case ($2.26). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.19 to $2.26) leaves room in how you read the outcome.
Key figures of Sagimet Biosciences Inc. Series A Common Stock
How large is the market capitalisation of Sagimet Biosciences Inc. Series A (SGMT)?
The market capitalisation of Sagimet Biosciences Inc. Series A Common Stock is $689M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sagimet Biosciences Inc. Series A (SGMT)?
Earnings per share at Sagimet Biosciences Inc. Series A Common Stock are $−1.26. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sagimet Biosciences Inc. Series A (SGMT)?
The return on equity (ROE) of Sagimet Biosciences Inc. Series A Common Stock is −24.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sagimet Biosciences Inc. Series A (SGMT)?
On an EBIT basis the return on assets of Sagimet Biosciences Inc. Series A Common Stock is −49.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sagimet Biosciences Inc. Series A (SGMT) generate?
The free cash flow of Sagimet Biosciences Inc. Series A Common Stock is −$45.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sagimet Biosciences Inc. Series A (SGMT) hold?
Sagimet Biosciences Inc. Series A Common Stock holds more cash than debt, $34.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sagimet Biosciences Inc. Series A Common Stock in the live analysis
One click puts Sagimet Biosciences Inc. Series A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 29, 2026